Sam Altman, the CEO of OpenAI and former president of Y Combinator, invests in science “moonshots” partly through Apollo Projects. His connections to the psychedelic field include the US$12 million 2021 Series A of Journey Colab (a mescaline-first psychedelic developer) and the roughly US$9.25 million 2025 seed round of Arcadia Medicine (empathogen therapeutics for anxiety).
Investor Context
Angel InvestorsInvestment Context
This stakeholder is listed as an Angel Investor within Angel Investors. Its public geography context is global. Public stage focus is not listed yet. Psychedelic-market posture: Psychedelic-Adjacent Focus.
Public Portfolio Examples
- Arcadia MedicineSeed - approximately $9.25 million - Oct 6, 2025
- Journey ColabSeries A - $12 million - Sep 7, 2021
Created from documented participation in 2 psychedelic financing rounds. Profile details beyond documented deals are unverified.
Investor Type
Angel Investor
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Stage focus is not listed yet.
Investment Focus Areas
Focus areas are not listed yet.
Recorded Investments
Oct 6, 2025
Seed - approximately $9.25 million
What Is Sam Altman's Involvement in MDMA Developer Arcadia, and Why Does It Matter?Sep 7, 2021
Series A - $12 million
Fenwick Represents Journey Colab in $12 Million Series A Financing